Skip to content

For Patients | Contact Us

About Us
- Our Team
- FAQs
- Our Team
- Milestones
Our Therapy
- Unmet Need
Procedure
Research
- News
Patients
Contact

About Us
- Our Team
- FAQs
- Our Team
- Milestones
Our Therapy
- Unmet Need
Procedure
Research
- News
Patients
Contact

Day: June 28, 2018

Money Talks (WLAE-TV): Matthew Altier and Paige Miller

Watch Video >

Disclaimer

* The information provided on this website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Targeted Osmotic Lysis (TOL) therapy is an investigational treatment and has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). TOL therapy is not available for general commercial use and is currently only available to patients enrolled in authorized clinical trials. Results from ongoing studies are preliminary and should not be interpreted as evidence of safety or efficacy. Always consult a qualified healthcare professional regarding any medical condition or treatment options.

Revolutionizing Cancer Treatment with Targeted Osmotic Lysis

Discover how Oleander Medical Technologies is addressing the unmet need for effective advanced-stage cancer treatments with our patented and promising technology.

Get in Touch to Learn More

Contact Us

(888) 555-5555
info@oleandermed.com

Facebook Linkedin X-twitter

© Oleander Technologies 2025. All rights reserved.